WO2005111605A3 - Biomarkers for the prediction and treatment of drug-induced diarrhoea - Google Patents

Biomarkers for the prediction and treatment of drug-induced diarrhoea Download PDF

Info

Publication number
WO2005111605A3
WO2005111605A3 PCT/EP2005/005266 EP2005005266W WO2005111605A3 WO 2005111605 A3 WO2005111605 A3 WO 2005111605A3 EP 2005005266 W EP2005005266 W EP 2005005266W WO 2005111605 A3 WO2005111605 A3 WO 2005111605A3
Authority
WO
WIPO (PCT)
Prior art keywords
prediction
biomarkers
drug
treatment
induced diarrhoea
Prior art date
Application number
PCT/EP2005/005266
Other languages
French (fr)
Other versions
WO2005111605A2 (en
Inventor
Muriel Saulnier
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Muriel Saulnier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Muriel Saulnier filed Critical Novartis Ag
Publication of WO2005111605A2 publication Critical patent/WO2005111605A2/en
Publication of WO2005111605A3 publication Critical patent/WO2005111605A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The invention provides biomarkers for the prediction of diarrhoea in a subject to whom a microtubule-stabilizing agent has been administered, based upon the gene expression of certain biomarker genes by the subject.
PCT/EP2005/005266 2004-05-17 2005-05-13 Biomarkers for the prediction and treatment of drug-induced diarrhoea WO2005111605A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57185304P 2004-05-17 2004-05-17
US60/571,853 2004-05-17

Publications (2)

Publication Number Publication Date
WO2005111605A2 WO2005111605A2 (en) 2005-11-24
WO2005111605A3 true WO2005111605A3 (en) 2006-03-16

Family

ID=35094415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005266 WO2005111605A2 (en) 2004-05-17 2005-05-13 Biomarkers for the prediction and treatment of drug-induced diarrhoea

Country Status (1)

Country Link
WO (1) WO2005111605A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104664A1 (en) * 2006-03-31 2011-05-05 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
GB201416015D0 (en) * 2014-09-10 2014-10-22 Univ Warwick Biomarker

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183380A1 (en) * 1996-12-02 2002-12-05 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
WO2005039573A2 (en) * 2003-10-06 2005-05-06 Novartis Ag Biomarkers for the prediction of drug-induced diarrhoea

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183380A1 (en) * 1996-12-02 2002-12-05 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
WO2005039573A2 (en) * 2003-10-06 2005-05-06 Novartis Ag Biomarkers for the prediction of drug-induced diarrhoea

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALTMANN K-H: "EPOTHILONE B AND ITS ANALOGS - A NEW FAMILY OF ANTICANCER AGENTS", MINI REVIEWS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 3, no. 2, March 2003 (2003-03-01), pages 149 - 158, XP008050865, ISSN: 1389-5575 *
CHEN JIE-GUANG ET AL: "Gene expression and mitotic exit induced by microtubule-stabilizing drugs.", CANCER RESEARCH. 15 NOV 2003, vol. 63, no. 22, 15 November 2003 (2003-11-15), pages 7891 - 7899, XP009055979, ISSN: 0008-5472 *
GALMARINI CARLOS MARÍA ET AL: "EPO-906 (Novartis).", IDRUGS : THE INVESTIGATIONAL DRUGS JOURNAL. DEC 2003, vol. 6, no. 12, December 2003 (2003-12-01), pages 1182 - 1187, XP008039860, ISSN: 1369-7056 *
PRUZANSKI WALDEMAR ET AL: "Microtubule depolymerization selectively down-regulates the synthesis of proinflammatory secretory nonpancreatic phospholipase A-2", LABORATORY INVESTIGATION, vol. 76, no. 2, 1997, pages 171 - 178, XP009056079, ISSN: 0023-6837 *
ROTHERMEL J ET AL: "EPO906 (EPOTHILONE B): A PROMISING NOVEL MICROTUBULE STABILIZER", SEMINARS IN ONCOLOGY, BETHESDA, MD, US, vol. 30, no. 3, SUPPL 6, June 2003 (2003-06-01), pages 51 - 55, XP008039857 *
WARTMANN M ET AL: "THE BIOLOGY AND MEDICINAL CHEMISTRY OF EPOTHILONES", CURRENT MEDICINAL CHEMISTRY. ANTI-CANCER AGENTS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 2, no. 1, January 2002 (2002-01-01), pages 123 - 148, XP009017278, ISSN: 1568-0118 *

Also Published As

Publication number Publication date
WO2005111605A2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2008070301A3 (en) Predicting lung cancer survival using gene expression
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
WO2007070280A3 (en) Use of deletion polymorphisms to predict, prevent, and manage histoincompatibility
WO2008008500A3 (en) Methods for making cancer prognoses based on the subcellular localization of biomarkers
WO2007082154A3 (en) B7-h1 and b7-h4 in cancer
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2007034221A3 (en) Non small cell lung cancer therapy prognosis and target
MX291201B (en) Fermentative production of fine chemicals.
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2007047408A3 (en) Promac signature application
WO2007124361A3 (en) Soluble b7-h1
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2006135886A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007044413A3 (en) Wwox gene, vectors containing the same, and uses in treatment of cancer
WO2007053648A3 (en) Compositions and methods for treating and diagnosing cancer
EA200801046A1 (en) NON-INVASIVE METHOD FOR IDENTIFYING TRANSITIONAL CELL CARCINOMA OF URINARY BUBBLE IN VITRO
WO2009036427A3 (en) Prostate cancer biomarkers
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2006074334A3 (en) Identification of rna targets using helicases
WO2008091948A3 (en) Galectin-3-binding, protein as a biomarker of cardiovascular disease
WO2005103229A3 (en) Transgenomic mitochondria, transmitochondrial cells and organisms, and methods of making and using
WO2010009171A3 (en) Src activation for determining cancer prognosis and as a target for cancer therapy
WO2006091861A3 (en) Compositions and methods relating to cns lymphoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase